BioLargo (BLGO) vs. Its Rivals Critical Comparison

BioLargo (NASDAQ:BLGO) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it contrast to its rivals? We will compare BioLargo to related companies based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, profitability, valuation and risk.

Profitability

This table compares BioLargo and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-568.74%	5.73%	-0.15%

Analyst Recommendations

This is a summary of current recommendations and price targets for BioLargo and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1274	1591	46	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 4.94%. Given BioLargo’s rivals higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares BioLargo and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.00
BioLargo Competitors	$6.65 billion	$206.77 million	67.66

BioLargo’s rivals have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

BioLargo has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s rivals have a beta of 1.78, meaning that their average share price is 78% more volatile than the S&P 500.

Summary

BioLargo rivals beat BioLargo on 8 of the 10 factors compared.

BioLargo Company Profile

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.